One death was caused by myocardial infarction in a patient subcutaneously receiving secukinumab (75 mg) in MEASURE-2, and one death due to suicide occurred after IL-17 inhibitor (ixekizumab) treatment in COAST-W [29]. The gene discussed is IL17A; the disease is myocardial infarction.